Intellipharmaceutics Announces Receipt of Nasdaq Notice

TORONTO, ON / ACCESSWIRE / November 26, 2018 / Intellipharmaceutics International Inc. (Nasdaq and TSX: IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release….


Read all

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.